It is suggested that the negative correlation between breast-feeding and insulin resistance and diabetes mellitus can be related to the presence of significant amounts of long-chain polyunsaturated fatty acids in the human breast milk. Based on this, it is proposed that provision of adequate amounts of long chain polyunsaturated fatty acids during the critical periods of brain growth and development can prevent or postpone the development diabetes mellitus.
Introduction
It is now believed that stimuli or insults induced during the perinatal period can have lifetime consequences, which is termed 'programming'. Programming stimuli may be generated endogenously, as in the case of hormonal signals, or they may be environmental. This 'programming' concept assumes that failure of a developing organism to progress from one stage of development to the next within the prescribed and preset time limits could lead to a permanent deficit (Susser & Levin, 1999) . This is supported by several human observational studies which have reported effects in later life of exposures such as radiation (Stewart et al, 1958; MacMahon, 1962) , famine (Stein et al, 1975) and viruses (Chess et al, 1971) . This idea has been elaborated by Barker (1992) , who suggested that impaired fetal growth might predispose to heart disease in later life. Coronary heart disease (CHD) is indeed common in men who were small at birth and at 1 y (Robinson, 2001) . Inadequate fetal nutrition may result in fetal adaptations that programme future propensity to adult disease. The most unfavourable growth pattern is smallness and thinness at birth, continued slow growth in early childhood, followed by acceleration of growth so that height and weight approach the population means. A continuing rise in body mass index (BMI) above the mean has been shown to be associated with impaired glucose tolerance (IGT; Robinson, 2001 ). This type of growth pattern: initial under nutrition followed by better nutrition, is particularly relevant to developing countries such as India, where the incidence of type 2 diabetes (which is characterized by carbohydrate, protein and lipid metabolic abnormalities and long-term complications involving eyes, kidneys, nerves and blood vessels) and IHD are rising rapidly coinciding with increasing urbanization and obesity. Studies have documented striking differences between rural and urban populations with respect to the prevalence of obesity and type 2 diabetes mellitus in India. For instance, the prevalence of obesity (BMI > 27) was reported as 3.6% in males and 6.6% in females in the rural population, but as high as 36.7% in males and 48.6% in females in the urban population. The prevalence of type 2 diabetes is higher in urban areas (10 -13%) than in rural areas (approximately 2.8%; Krishnaswamy & Prasad, 2001 ). The exact reason for the difference in the prevalence of obesity and type 2 diabetes between the rural and urban populations is not clear, but it is relevant to note that the prevalence of breast-feeding is on the decline in India, especially in the urban areas. It is also interesting to note that Indian babies are exceptionally small, with a mean birth weight of 2700 g, and 30 -35% have a birth weight of 2650 g or less (Robinson, 2001; Krishnaswamy & Prasad, 2001) . The mothers of these children are short and underweight, with a mean BMI of only 18. These small babies have a low muscle mass, small viscera and a relative excess of fat -a body composition that is particularly suited to induce the development of insulin resistance. This is supported by the observation that lower birth weight and higher BMI in childhood are associated with IGT in these children (Robinson, 2001) . These studies indicate that perinatal nutrition is an important determinant of adult diseases, an issue of major public health importance.
Tumour necrosis factor-a and diabetes mellitus
There are mainly two types of diabetes mellitus (DM): type 1 and type 2. The immune-mediated destruction of b-cells that occurs in type 1 DM involves both humoral and cell-mediated mechanisms. T and B lymphocytes, macrophages, granulocytes and NK cells are activated to release interleukin-1 (IL-1) and tumour necrosis factor-a (TNF-a) and interferon-g (IFN-g) to destroy the b-cell in type 1 DM (Mandrup-Poulsen et al, 1986; Dunger et al, 1996) . Environmental agents such as drugs, chemicals and viruses increase the risk of genetically prone individuals developing type 1 DM. On the other hand, type 2 DM is characterized by insulin resistance and hyperinsulinaemia. Elevated plasma TNF-a levels have been associated with obesity and insulin resistance, hypertriglyceridaemia and glucose intolerance (Hotamisligil, 1999; Jovinge et al, 1998; Das, 1999) , which are seen in type 2 DM. Hence, methods designed to block or antagonize the actions of TNF-a may prevent both type 1 and type 2 diabetes mellitus. One endogenous factor that has a negative feedback control on the production of TNF-a and other pro-inflammatory cytokines is long chain polyunsaturated fatty acids (LCPUFAs; Kumar & Das, 1994; Kumar et al, 1992; Endres et al, 1989) .
LCPUFAs and type 1 diabetes
Several case -control studies found a negative correlation between frequency and duration of breast-feeding and type 1 diabetes (Schrezenmeir & Jagla, 2000; Villalpando & Hamosh, 1998) . This beneficial action has been attributed to reduced exposure to diabetogenic agents (especially viruses). Breast-feeding for 13 weeks reduced the incidence of gastrointestinal illness and respiratory illness during the first year of life (Wilson et al, 1998) . It is likely that exclusive breastfeeding protects against bacterial and viral infections and prevents T-cell and humoral responses related to cow's milk proteins and thus protects from environmental factors that can trigger type 1 diabetes. Breast milk is a rich source of LCPUFAs (Fidler et al, 2000; Beijers & Schaafsma, 1996; de la Presa-Owens et al, 1996; Koletzko et al, 1988 Koletzko et al, , 1992 see Table 1 for fatty acid composition of human breast milk). Hence, it is possible that these fatty acids are able to protect b-cells and, thus, prevent diabetes. This is supported by the results of our animal studies in which it was observed that pre-treatment with LCPUFAs such as gamma-linolenic acid (GLA), arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) prevents alloxan-induced destruction of b cells both in vitro and in vivo (Mohan & Das, 2001; . These results are supported by the work of Stene et al (2000) , who showed in a populationbased case -control study that cod liver oil, a rich source of EPA and DHA, taken during pregnancy was associated with reduced risk of type 1 diabetes in the offspring. This suggests that LCPUFAs, when present in adequate amounts, prior to or at the time of exposure to the diabetogenic agent can protect b-cells and prevent type 1 diabetes. Although the exact mechanism by which LCPUFAs protect b-cells is not known, both cyclo-oxygenase and lipoxygenase inhibitors did not block the beneficial action of LCPUFAs in vitro and in vivo (Mohan & Das, 2001; suggesting that fatty acids themselves are active. Further, LCPUFAs prevented alloxan-induced apoptosis of the pancreatic b-cells ). Mice deficient in poly (ADP-ribose) polymerase (PARP) activity are resistant to streptozotocin (both alloxan and streptozotocin have similar action on b cells)-induced b-cell death (Burkart et al, 1999) . Hence, the possibility that LCPUFAs inhibit PARP activity and thus prevent DM is likely, but needs to be studied.
LCPUFAs and type 2 diabetes mellitus
In Pima Indians, type 2 DM was less common among breastfed children compared with those exclusively bottle-fed (Pettitt & Knowler, 1998; Pettitt et al, 1997) . A strong association between the method of infant feeding in the first weeks after birth and glucose tolerance in adults aged 48 -53 y was reported (Ravelli et al, 2000) . Subjects who were bottle-fed had a higher mean 120 min plasma glucose concentration after a standard oral glucose tolerance test than those who were exclusively breast-fed. Breast-fed infants had a significantly higher percentage of DHA and total percentage of LCPUFAs in muscle phospholipids and lower plasma glucose levels compared with the formula-fed group There could be minor variations in the content of each fatty acid in the human milk.
Can LCPUFAs prevent diabetes? UN Das (Baur et al, 1998 ). An inverse correlation between fasting plasma glucose and the percentage of both DHA and total LCPUFAs was reported (Borkman et al, 1993) . The secretion of TNF-a, which is cytotoxic to pancreatic b cells (Dunger et al, 1996) and plays a major role in inducing insulin resistance (Hotamisligil, 1999; Jovinge et al, 1998; Das, 1999) , is suppressed by LCPUFAs (Kumar & Das, 1992; Endres et al, 1989) . Based on this, the beneficial action of breast-feeding in the prevention of type 1 DM, insulin resistance and type 2 diabetes can be attributed to the presence of significant amounts of LCPUFAs in human breast milk. How do LCPUFAs prevent insulin resistance and type 2 DM? One possibility is that, when substantial amounts of LCPUFAs are incorporated into the cell membrane, the membrane becomes more fluid and enhances the number of insulin receptors on the membrane, and increases the affinity of insulin to its receptors, and insulin action (Das, 1994a; Ginsberg et al, 1982; Somova et al, 1999) . This attenuates insulin resistance. However, other unknown mechanisms by which LCPUFAs may exert this beneficial action should also be kept in mind. EPA and DHA rich oil prevented insulin resistance and hypertension in a fructosefed rat model (Huang et al, 1997) . Purified EPA ethyl ester reduced insulin resistance and decreased the incidence of type 2 DM in OLETF and WBN=Kob rats respectively (models of spontaneous type 2 DM) by modifying the phospholipid fatty acid composition of the skeletal membrane (Mori et al, 1997; Nobukata et al, 2000) . The observation that (a) there is a significant correlation between insulin secretion and action and AA (Pelikanova et al, 1989) , (b) an inverse relationship exists between fasting plasma insulin and the percentage of AA in erythrocyte fatty acids (Clifton & Nestel, 1998) , and (c) decreased insulin sensitivity is associated with decreased concentrations of PUFAs in skeletal muscle phospholipids in normal men (Borkman et al, 1993) suggests that PUFAs can modulate insulin sensitivity and insulin resistance. It was reported that long-term (6 months) fish oil (a rich source of EPA and DHA) supplementation to patients with type 2 DM did not produce any significant changes in blood glucose and insulin-mediated glucose uptake (Rivellese et al, 1996) . This negative result could, in part, be due to a decrease in AA levels induced by increased intake of EPA, suggesting that a balanced intake of AA, EPA and DHA is important. Based on this, it is suggested that LCPUFAs prevent the development of insulin resistance, hypertension and DM but are ineffective once these diseases set in. This may also explain why breast-feeding (a rich source of LCPUFAs) is associated with decreased incidence of insulin resistance, hypertension and DM in the adult (Pettitt & Knowler, 1998; Pettitt et al, 1997; Ravelli et al, 2000; Singhal et al, 2001; Das, 2001a) .
Ventromedial hypothalamic lesion and type 2 diabetes mellitus
Induction of lesions in the ventromedial hypothalamus (VMH) in rats induce instant hyperphagia and excessive weight gain (Axen et al, 1994) , fasting hyperglycaemia, hyperinsulinaemia, hypertriglyceridaemia and impaired glucose tolerance (Dube et al, 1999) . Intraventricular administration of neuropeptide Y (NPY) antibodies abolished the hyperphagia and ob mRNA (leptin mRNA) in these animals. This suggests that increased release or action of NPY is responsible for hyperphagia and obesity seen in VMH-lesioned animals and that the ob gene might be up-regulated even in non-genetically obese animals (Dube et al, 1995; Funahashi et al, 1995) . Streptozotocin-induced diabetic rats showed increase in NPY concentrations in the paraventricular and ventromedial (VMH) and lateral hypothalamic areas (Williams et al, 1989) whereas VMHlesioned rats showed selectively decreased concentrations of norepinephrine and dopamine in the hypothalamus (Takahashi et al, 1994) . Long-term infusion of norepinephrine plus serotonin into the VMH impairs pancreatic islet function in as much as VMH norepinephrine and serotonin levels are elevated in hyperinsulinaemic and insulin-resistant animals (Ohtani et al, 1997) . These changes in the hypothalamic neurotransmitters were restored to near normal concentrations after insulin therapy. Thus, dysfunction of VMH can impair pancreatic islet function and cause metabolic abnormalities similar to those seen in type 2 diabetes.
VMH-lesioned rats have suppressed splenic NK cell activity, especially when these animals were hyperphagic and obese (Katafuchi et al, 1994) . The brain produces interferon-a (IFN-a) , interleukin-1 (IL-1), IL-2 and several other cytokines including TNF in response to non-inflammatory and inflammatory stress (Horin et al, 1998; Tanebe et al, 2000) . In rat brain slice preparations, TNF-a decreased the firing rate of the VMH neurons (Katafuchi et al, 1997) . Thus, a close association exists between hypothalamic monoamines, islet cell function and cytokines.
TNF-a causes neuronal cell death (Venters et al, 1999 (Venters et al, , 2000 , whereas LCPUFAs have significant neuroprotective action (Lauritzen et al, 2000) and inhibit the production of IL-1, IL-2 and TNF-a both in vitro and in vivo (Kumar & Das, 1992 Endres et al, 1989) . TNF-a participates in the pathogenesis of both type 1 and type 2 diabetes. Breast milk is rich in LCPUFAs, especially AA, EPA and DHA, which also constitute a significant proportion of the total fatty acids in the brain, where they are predominantly associated with membrane phospholipids. It is possible that when the concentrations of LCPUFAs are inadequate, especially during the critical period of brain growth, which is from third trimester to 2 y post-term, TNF-a levels tend to be high and this can cause damage to VMH neurons. This in turn leads to hyperphagia, hyperglycaemia, hyperinsulinaemia, hypertriglyceridaemia and IGT. This may explain the negative correlation observed between adequate breastfeeding and insulin resistance and type 2 and type 1 diabetes. It is also interesting to note the close relationship between LCPUFAs, insulin receptors in the brain and type 2 diabetes.
Can LCPUFAs prevent diabetes? UN Das LCPUFAs, insulin receptors in the brain and type 2 diabetes mellitus
Insulin signalling plays an important role in the regulation of food intake, neuronal growth and differentiation, regulates neurotransmitter release and synaptic plasticity in the CNS (Wan et al, 1997; Bruning et al, 2000) . In mice with neuron-specific disruption of the insulin receptor gene (NIRKO mice), brain development and neuronal survival were normal. However, female NIRKO mice showed increased food intake, and both male and female mice developed diet-sensitive obesity with increases in body fat and plasma leptin levels, insulin resistance, hyperinsulinaemia and hyper-triglyceridaemia, features that are seen in type 2 diabetes mellitus. This suggests that decrease in the number of insulin receptors, a defect in the function of insulin receptors, insulin lack or resistance in the brain can lead to the development of type 2 diabetes even when pancreatic b cells are normal both qualitatively and quantitatively. These results are supported by the observation that intraventricular injection of insulin inhibits food intake (Bruning et al, 2000) . LCPUFAs have important effects on cell membrane and cellular properties of neural tissue. In infants, LCPUFAs are preferentially accumulated by the brain during the last trimester of pregnancy and the first months of life. Adequate amounts of AA and DHA are essential for optimal development and function of central nervous system (reviewed in Salem et al, 1996) . Infants as small as 2 kg and 32 weeks of gestation are capable of elongation and desaturation of EFAs, LA and ALA, and form AA and DHA, respectively. However, vegetable oil-based infant feed formulas lead to sub-optimal neural development and performance due to decrease in brain DHA content (Salem et al, 1993; Farquharson et al, 1995) .
Human infants accumulate AA, EPA and DHA from maternal=placental transfer, consumption of human milk, and synthesis from LA and ALA. It is known that AA stimulates glucose uptake in cerebral cortical astrocytes and thus may play a role in the regulation of energy metabolism in the cerebral cortex (Yu et al, 1993) . Glucose, in turn, is known to enhance ACh release in the brain (Ragozzino et al, 1996) . Since AA enhances glucose uptake and, in turn, glucose augments ACh release, it is reasonable to assume that AA can enhance ACh release (Das, 2001b) . Indeed, DHA, another LCPUFA increases cerebral ACh levels and improves learning ability in rats (Minami et al, 1997) . In brain, ACh modulates neuronal functions including long-term potentiation and synaptic plasticity in neuronal circuits that are involved in learning and memory, and interacts with dopamine receptor in hippocampus (Hersi et al, 2000) . This is interesting since decreased numbers of dopamine receptors or dopamine concentrations have a role in obesity (Wang et al, 2001) , a condition that is frequently associated with type 2 diabetes. The brain is rich in insulin receptors (Bruning et al, 2000; Hill et al, 1986; Das, 2001e) . Insulin receptor tyrosine kinase substrate p58=53 and the insulin receptor are components of synapses in the CNS (Abott et al, 1999) . Insulin and energy restriction enhance the activities of desaturases (reviewed in Das, 1991 Das, , 2000a and so can increase the formation of LCPUFAs from their respective precursors (see Figure 1) . TNF-a-induced neuronal death can be antagonized by IGF-1 and insulin (Venters et al, 1999 (Venters et al, , 2000 . AA, DHA and other LCPUFAs have significant neuroprotective action (Lauritzen et al, 2000) and inhibit the production of IL-1, IL-2 and TNF-a both in vitro and in vivo (Kumar & Das, 1992; Endres et al, 1989) . Both insulin and LCPUFAs regulate superoxide anion generation and enhance the production of eNO (endothelial NO) (Das, 1994b (Das, , 2000b (Das, , 2001c (Das, , d, 2002a Satomi et al, 1985; Boichot et al, 1999) . NO has antiinflammatory actions under certain circumstances (Guidot et al, 1996) and can quench free radicals. IGF-I and, possibly, insulin enhance ACh release from rat cortical slices (Nilsson et al, 1988) . ACh in turn has anti-inflammatory actions (Borovikova et al, 2000) and is also a potent stimulator of eNO synthesis (Xu et al, 1996) . Based on this, it is suggested that the concentrations of LCPUFAs are increased in the brain by the action of insulin and IGF-I on desaturases, which in turn enhances the brain ACh (this is in addition to the ability of insulin and IGF-I to directly enhance ACh levels in the brain) and suppress the production of TNF-a, a neurotoxic molecule. Insulin, ACh and LCPUFAs suppress the production of TNF-a and augment the synthesis of eNO. Both ACh and eNO in addition to their neuroprotective action interact with other neurotransmitters. Thus, insulin, IGF-I, ACh and LCPUFAs protect brain from insults induced by TNF-a and other molecules. 
Can LCPUFAs prevent diabetes? UN Das
Since LCPUFAs enhance the number of insulin receptors and attenuate insulin resistance (Burkart et al, 1999; Pettitt & Knowler, 1998; Pettitt et al, 1997; Ravelli et al, 2000; Baur et al, 1998; Borkman et al, 1993) , one important function of LCPUFAs in the brain could be to ensure the presence of adequate number of insulin receptors. This assumes added significance in the light of the observation that NIRKO mice showed all the features of type 2 diabetes (Bruning et al, 2000) . Thus, a defect in the metabolism of LCPUFAs or when adequate amounts of LCPUFAs are not incorporated into the neuronal cell membranes during the fetal development and infancy may lead to a defect in the expression and=or function of insulin receptors in the brain. This may lead to type 2 diabetes as seen in NIRKO mice.
Conclusion and therapeutic implications
The negative correlation observed between breast-feeding and insulin resistance and DM can be related to the presence of significant amounts of LCPUFAs in the human breast milk. I suggest that the increased prevalence of type 2 diabetes mellitus seen in certain populations recently could be due to a concomitant decrease in breast-feeding. This possibility can be verified by studying whether there is a negative correlation between breast-feeding and the incidence of DM in these populations. Formula feeds contain only linoleic acid (LA) and alpha-linolenic acid (ALA), which are essential fatty acids (EFAs), but not their longer chain metabolites GLA, DGLA, AA, EPA, DPA (docosapentaenoic acid, 22:5 o-3) and DHA, which are present in the human milk. This is an important difference. Although infants have the capability to synthesize these longer chain fatty acids from LA and ALA, the rate of formation appears to be not adequate in the early stages of life, especially in pre-term infants (Carlson et al, 1985; Cunnane et al, 2000) . Hence, the amounts of LCPUFAs formed may be inadequate to support the optimal neural development. As a result, the development, expression and maintenance of insulin receptors will be low, whereas the concentrations of pro-inflammatory cytokines such as TNF-a, which participates in neuronal plasticity and neurodegenerative conditions (Mattson et al, 2001) , will be high. This leads to a decrease in the expression and number of insulin receptors in the brain and thus the onset of obesity, insulin resistance and diabetes mellitus as seen in the NIRKO mice. Thus, a marginal deficiency of LCPUFAs during the critical phases of fetal and infant growth can have a profound effect on subsequent health (see Figure 2) . Impaired fetal growth seems to increase the risk for adult diseases: insulin resistance, impaired glucose tolerance, type 2 diabetes mellitus, hypertension and coronary heart disease (Robinson, 2001 ). The hypothesis proposed by Barker (1992) predicts that coronary heart disease and impaired glucose tolerance will be more common in populations that are undergoing transition from sparse to better nutrition such as India, where the incidence of insulin resistance, type 2 diabetes mellitus, hypertension and coronary heart disease is assuming epidemic proportions (Krishnaswamy & Prasad, 2001) . However, the relationship relating birth-weight to later outcomes has been disputed (Lucas et al, 1999) . It was suggested that much of what was claimed to be fetal in origin may, in fact, relate to postnatal nutrition and growth (Lucas et al, 1999) . It is possible that both fetal and postnatal nutrition and growth play a significant role in adult diseases. If this is true, what is the most significant perinatal nutritional factor(s) that can induce lifetime effects on metabolism, growth, and neurodevelopment and on major adult diseases? I suggest that this nutritional factor could be the LCPUFA content of human breast milk. It is true that breast milk contains several bioactive factors in addition to LCPUFAs. Breast-fed infants showed decreased incidence of obesity (Das, 2001b; von Kries et al, 2000) , insulin resistance (Baur et al, 1998) , hypertension (Das, 2001a; Singhal et al, 2001) , diabetes mellitus (Schrezenmeir & Jagla, 2000; Pettitt et al, 1997) , and CHD (Fall et al, 1992) in later life. LCPUFAs have beneficial actions in all these conditions (reviewed in Mohan & Das, 2001; Stene et al, 2000; Borkman et al, 1993; Das, 1994a Das, , 2000c Das, , 2001a . In view of this overlap of actions between breast-feeding and LCPUFAs, it is reasonable to suggest that some of the beneficial actions of human breast milk can be attributed to their content of LCPUFAs. These LCPUFAs when fed (either through breast milk or externally) during the critical periods of growth (third trimester to 2 y post-term) will accumulate not only in the specified areas of the brain but also in vessel walls Can LCPUFAs prevent diabetes? UN Das including endothelium, kidney, heart and other tissues and, thus, may counteract the pathological mechanisms that tend to induce diabetes mellitus, insulin resistance, hypertension and CHD (Das, 2002b) . Clearly, more studies are needed to confirm or refute this suggestion. It is known that children born to women with gestational diabetes mellitus (GDM) have a higher incidence of diabetes. Wijendran et al (2000) reported that umbilical cord vein erythrocyte phospholipid AA and DHA concentrations were significantly lower in women with GDM in comparison to healthy pregnant women. Maternal HbA 1c (glycosylated hemoglobin) was inversely correlated to fetal erythrocyte phospholipid DHA and AA in GDM. This indicates that there is impairment in fetal accretion of DHA and AA in GDM. This supports the proposal that decreased accumulation of perinatal LCPUFAs increases the incidence of DM. However, studies relating the incidence of diabetes in children born of GDM women as function of breast-feeding have not been performed. If the hypothesis presented here is correct, it is expected that the incidence of diabetes in those who were breast-fed will be low.
A close association between poor fetal growth and adult diseases (Robinson, 2001; Barker, 1992) has been suggested. Could this be explained in terms of the hypothesis presented here? Ozanne et al (1998) showed that growth retardation due to maternal protein restriction induced a decrease in the ratio of DHA to DPA in both muscle and liver in their offspring. The D-5-desaturase activity in hepatic microsomes showed a reduction in the low-protein offspring, which was negatively correlated with fasting plasma insulin levels compared to controls. This suggests that fetal growth retardation inhibits the activity of D-5-desaturase, a key enzyme involved in the formation of LCPUFAs in the body. This is interesting in the light of the observation that in pre-term infants fed commercial formulas with LA, AA in plasma and erythrocyte phospholipids declined for months after birth and remained low for 5 months. In these infants, AA status correlated with one or more measures of normalized growth until 12 months. Dietary AA improved first year growth of pre-term infants (Carlson et al, 1985) . Studies performed both in experimental animals and humans showed that excess EPA and DHA inhibited both D 6 and D5 desaturases (Raz et al, 1997) , causing a depletion in AA, which led to impaired growth, resulting in lower weight, length and head circumference (Hamosh, 1998; Amusquivar et al, 2000) . On the other hand, studies done in the fish-eating community of the Faroe Islands suggested that intake of seafood rich in long-chain o-3 fatty acids increased birth weight by prolonging gestation (Olsen et al, 1986) and=or by increasing the fetal growth rate (Olsen et al, 1987 (Olsen et al, , 1990 . These studies imply that a balanced intake of AA, EPA and DHA is essential for proper growth and development of the fetus and for postnatal development. This is supported by the fact that breast milk, the most ideal food for the newborn, contains substantial amounts of AA, EPA and DHA (see Table 1 ).
It is also important to note that many co-factors are necessary for optimal EFA metabolism. There are also factors that can interfere with the metabolism of LA and ALA such that their long-chain metabolites are not formed in adequate amounts (see Figure 1) . In view of this, it is important that infants receive adequate amounts of the co-factors that are necessary for optimal EFA metabolism. Hence, it is suggested that infant feed formula should contain adequate amounts of various LCPUFAs (similar to the composition as is present in human milk) and co-factors that are necessary for the proper metabolism of EFAs. When such balanced supplementation is given to infants from birth until 2 y post-term, it may reduce the incidence of diabetes mellitus (both type 1 and type 2).
It was reported that the calculated transfer of dietary LA and AA into breast milk was 32.8 AE 18.0% and 11.8 AE 6.6% respectively, whereas AA originating from conversion of dietary LA contributed only 1.1% to the total milk AA secreted (Prado et al, 2001 ). Thus, it was observed that little milk AA originates from conversion of LA and that 70% of LA and 90% of AA secreted in human breast milk is not derived from direct intestinal absorption, indicating that maternal body stores are the major source of milk LA and AA in the lactating women (Prado et al, 2001 ). This indirectly emphasizes the importance of providing various LCPUFAs from external sources to all women so that their body stores of LCPUFAs are adequately replenished so that when they are pregnant the fetus will be able to receive adequate amounts of these fatty acids. Infant feed formula may be supplemented with adequate amounts of various LCPUFAs (similar to the composition of human milk) from birth to 2 y post-term so that the incidence of diabetes mellitus is likely to be reduced. It is important that these LCPUFAs may also be provided to all pregnant females so that the fetus receives adequate amounts of these fatty acids . Since the brain keeps producing neurons even in adulthood (Barinaga et al, 1998) , it may be necessary to supplement LCPUFAs even after infancy, keeping in view the possible adverse effects of excess intake of these fatty acids.
